CN113166087B - 屏蔽剂及其用途 - Google Patents

屏蔽剂及其用途 Download PDF

Info

Publication number
CN113166087B
CN113166087B CN201980076992.7A CN201980076992A CN113166087B CN 113166087 B CN113166087 B CN 113166087B CN 201980076992 A CN201980076992 A CN 201980076992A CN 113166087 B CN113166087 B CN 113166087B
Authority
CN
China
Prior art keywords
cancer
imaging
compound
effective amount
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980076992.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166087A (zh
Inventor
C·P·利蒙
I·R·弗拉霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CN113166087A publication Critical patent/CN113166087A/zh
Application granted granted Critical
Publication of CN113166087B publication Critical patent/CN113166087B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980076992.7A 2018-09-21 2019-09-19 屏蔽剂及其用途 Active CN113166087B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734690P 2018-09-21 2018-09-21
US62/734690 2018-09-21
PCT/US2019/051903 WO2020061293A1 (en) 2018-09-21 2019-09-19 Shielding agents and their use

Publications (2)

Publication Number Publication Date
CN113166087A CN113166087A (zh) 2021-07-23
CN113166087B true CN113166087B (zh) 2024-05-10

Family

ID=69887812

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980076992.7A Active CN113166087B (zh) 2018-09-21 2019-09-19 屏蔽剂及其用途

Country Status (5)

Country Link
US (1) US20210323985A1 (https=)
EP (1) EP3853213A4 (https=)
JP (2) JP7429688B2 (https=)
CN (1) CN113166087B (https=)
WO (1) WO2020061293A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590783A1 (ru) * 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US20250332265A1 (en) * 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778910A (zh) * 2006-11-08 2010-07-14 分子制药洞察公司 谷氨酸的异质二聚体
CN103930432A (zh) * 2011-06-15 2014-07-16 癌靶技术有限责任公司 螯合的psma抑制剂
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN111801121A (zh) * 2017-04-11 2020-10-20 约翰霍普金斯大学 在psma靶向癌症成像或放疗期间用于健康组织保护的2-pmpa前药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
EA201590783A1 (ru) * 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
PL3177632T3 (pl) 2014-08-06 2022-06-13 The Johns Hopkins University Proleki inhibitora antygenu błony swoistego dla stercza (PSMA)
JP2017530109A (ja) 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778910A (zh) * 2006-11-08 2010-07-14 分子制药洞察公司 谷氨酸的异质二聚体
CN103930432A (zh) * 2011-06-15 2014-07-16 癌靶技术有限责任公司 螯合的psma抑制剂
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN111801121A (zh) * 2017-04-11 2020-10-20 约翰霍普金斯大学 在psma靶向癌症成像或放疗期间用于健康组织保护的2-pmpa前药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for Pet Imaging;Eder, M; 等人;《Bioconjugate Chemistry》;第23卷(第4期);688-697 *

Also Published As

Publication number Publication date
CN113166087A (zh) 2021-07-23
EP3853213A1 (en) 2021-07-28
EP3853213A4 (en) 2022-07-06
JP2024028840A (ja) 2024-03-05
US20210323985A1 (en) 2021-10-21
JP7429688B2 (ja) 2024-02-08
JP7748438B2 (ja) 2025-10-02
JP2022501383A (ja) 2022-01-06
WO2020061293A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
CN113166087B (zh) 屏蔽剂及其用途
KR102902487B1 (ko) 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도
ES2960030T3 (es) Tratamiento de células cancerosas que sobreexpresan receptores de somatostatina utilizando derivados de ocreótido quelados con radioisótopos
JP7840115B2 (ja) 癌を治療する方法
AU2019345320B2 (en) Methods of treating cancer
CN101626787A (zh) 诊断的和治疗的环氧合酶-2结合配体
CN116217505B (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
JP2025503451A (ja) 炭酸脱水酵素ｉｘリガンド
CN121909051A (zh) 靶向成纤维细胞活化蛋白的组合物及其使用方法
WO2026039503A1 (en) Fibroblast activation protein-targeted compositions and methods of use thereof
HK40047004A (en) Methods of treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant